In Response: We want to thank Dr. Fuad Lechin for his comments about the impact of natural killer (NK) cells in different tumor types including prostate, gastric, mammary and non-Hodgkin lymphoma. His finding that clinical improvement correlated with an increased cytotoxicity against K562 cells, a classical NK target cell line, is of major interest and further confirmed our hypothesis that Hsp70 plasma membrane expression serves as a tumor-specific, stress-inducible recognition site for NK cells. Screening of more than 800 different tumor samples and corresponding normal tissues including lung, colorectal, stomach, pancreas, mammary, head and neck cancers, and leukemic blasts revealed that Hsp70 membrane localization was frequently detected on human tumors (50 -80% of the cases) but never on normal tissues (refs. 1 and 2; Gabriele Multhoff, Lydia Rossbacher, Mathias Gelermann unpublished observation). Also K562 cells present Hsp70 on their plasma membrane (3). This Hsp70 membrane expression could be further enhanced by exogenous stress induced by chemotherapy (4, 5) . High Hsp70 levels have been found to exert dual functions: i.e., on the one hand, they mediate protection against chemotherapy-induced effects (6); on the other hand, they serve as a danger signal for NK cells (7) . Incubation of NK cells with the Hsp70-derived peptide "TKD" (TKDNNLLGRFELSG, amino acid 450 -463), mimicking the danger signal, was able to enhance the cytolytic and migratory capacity of NK cells toward Hsp70 membrane-positive tumor cells (8) . Granzyme B could be identified as the effector protease inducing programmed cell death in Hsp70 membrane-positive tumor cells (9) . After rein-fusion of ex vivo Hsp70-activated autologous NK cells in tumor patients, granzyme B serum levels were found to be elevated (10) . Furthermore, Hsp70 but neither Hsp60 nor Hsp65 antibody levels in the serum also seemed to be affected. The prognostic value of these serum parameters and the clinical efficacy of "TKD"-activated NK cells will be addressed in a multicenter clinical phase II trial in the near future.
